Grants4Apps Accelerator and new Dealmaker now open for submissions

The Grants4Apps Accelerator Berlin is back and this time with an additional track for the mature startups out there: The Dealmaker. Up to five startups will be selected for the 100-day Accelerator program in Berlin. The new Dealmaker is all about quality facetime between you and Grants4Apps experts for one full day.

Grants4Apps Accelerator Berlin 2017

Startups receive € 50,000 each as well as office space in the Bayer Pharmaceuticals Headquarters. Additionally, C-level mentors will support in refining business models, validating technologies and more.

The Grants4Apps team is looking for startups with innovative healthcare solutions. The team is open for any healthcare topics and will give special attention to Bayer-relevant focus areas. This year Grants4Apps is focusing on digital health solutions in the areas of Nephrology (e.g., Chronic Kidney Disease), Women's Health (e.g., Endometriosis), Pulmonology (e.g., Pulmonary Hypertension), Cardiology (e.g., Atrial Fibrillation), Hematology, Oncology, Radiology, Infectious Diseases and Ophthalmology (e.g., Diabetic Retinopathy).

Grants4Apps is also calling for collaboration projects using software or hardware to be applied in clinical trials and medical IT using state-of-the art-technologies such as artificial intelligence, machine learning, deep learning, sophisticated algorithms, bioinformatics, genomics analysis, novel approaches for Electronic Health Records (EHR) etc. - in short: highly innovative technologies with a taste for excellent simplicity and unbeatable user experience focus.

Submission deadline: 31 May 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/accelerator-berlin-2017/

Dealmaker Berlin 2017

Don't need acceleration? Want to gain Bayer as a potential customer? Then this is for you! Mature startups can apply to solve specific 'Bayer challenges'. The top startup matches will have the opportunity to come to Berlin in September (travelling costs will be covered by Bayer) and to sign a potential project deal, please find the challenge you can solve.

If there is a match, you will be inviteed to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.

Applicants are asked to address one or multiple challenges. However, the Dealmaker is also open for other solutions that help healthcare providers or patients, as well as products dedicated to preventing or diagnosing diseases or improving pharmaceutical processes.

Submission deadline: 30 June 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/dealmaker-berlin-2017/

About Grants4Apps®
We connect health startups with industry experts and help the best talents to thrive within the digital healthcare universe. We are looking for startups beyond the ideation phase developing health technology or IT solutions that can connect and empower patients or healthcare stakeholders.

There are no boundaries to creativity!

Most Popular Now

ACE2 protein protects against severe COVID-19

Female COVID-19 patients face less severe disease complications and a lower risk of dying than male patients thanks to hormones and chromosomes that contribute to a stron...

Neutralizing antibodies protect against severe COV…

Understanding the body's immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines. Of particular...

How SARS-CoV-2 interacts with cells

SARS-CoV-2 infections pose a global threat to human health and a formidable research challenge. One of the most urgent tasks is to gain a detailed understanding of the mo...

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

Vir Biotechnology and GSK announce start of NIH-sp…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in a new sub-trial of the National Ins...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EM...

Pfizer and BioNTech receive authorization in the E…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...